NASDAQ · CAMP
CAMP4 Therapeutics Corporation
$3.90+$0.25 (+6.85%)
CAMP4 Therapeutics Corporation’s quoted price sits in the lower half of its reported 52-week range, 49.68% below the high.
Loading market information…
NASDAQ · BMEA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Biomea Fusion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.2% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Biomea Fusion, Inc.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of -$0.18. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Biomea Fusion, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:52 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 31, 2025 |
| -$0.81+19.0% vs estimate |
| $1.22M |
| Q3 2024 | Oct 29, 2024 | -$0.91+13.33% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.90+$0.25 (+6.85%)
CAMP4 Therapeutics Corporation’s quoted price sits in the lower half of its reported 52-week range, 49.68% below the high.
$1.22+$0.04 (+3.39%)
ALX Oncology Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.14% below the high.
$9.14-$0.15 (-1.61%)
Sutro Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.16% below the high.
$2.65$0.00 (0.0%)
Repare Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
$7.80-$0.19 (-2.32%)
Immunic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.28% below the high.
$3.81+$0.05 (+1.33%)
Unicycive Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.41% below the high.
$1.35-$0.06 (-4.26%)
Cibus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.79% below the high.
$4.36$0.00 (0.0%)
Adverum Biotechnologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 28.17% below the high.
